Effects of Lemon Verbena Extract Supplementation in Sub-ADHD Children

NCT ID: NCT05476549

Last Updated: 2023-12-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-04

Study Completion Date

2023-08-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to investigate the effects of 15 mg/kg lemon verbena, in comparison to placebo, on the attention deficit hyperactivity disorder (ADHD) type behaviour and cognitive function of children who do not have a diagnosis of ADHD, but who exhibit high scores (highest tertile) on ADHD behaviour parameters. Multiple aspects of mood will also be assessed.

The proposed randomised, double-blind, placebo-controlled, parallel groups design methodology will assess the psychological effects of 15 mg/kg lemon verbena extract and a matched placebo prior to and after 4 and 8 weeks of supplementation. The trial will utilise the COMPASS cognitive assessment system (Northumbria University) and a range of mood measures during laboratory testing visits.

Parents and children will also take part in a concomitant smartphone study, comprising the collection of the parent's assessment of the child's behaviour/cognitive function and the child's self-report of the same, plus their mood. These assessments will take place on Days -1, 14, 28, 42 and 56.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Behavior, Child Cognitive Change

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lemon verbena

Group Type EXPERIMENTAL

Lemon verbena

Intervention Type DIETARY_SUPPLEMENT

Lemon verbena supplement administered at an estimated daily dose of 15mg/kg

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Placebo supplement containing carrier material only

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lemon verbena

Lemon verbena supplement administered at an estimated daily dose of 15mg/kg

Intervention Type DIETARY_SUPPLEMENT

Placebo

Placebo supplement containing carrier material only

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are in good health as reported by themselves and their parent/guardian
* Are aged 8 to 17 years at the time of giving assent and parents giving consent
* Have a sex and age-related BMI less than the 98th centile according to the local NHS guidelines
* Are rated by their parents as having a high score (T score of ≥60) on both the Connors 3 subscales of Inattention and Hyperactivity/Impulsivity.
* Have no current diagnosis of ADHD
* Have no relevant food intolerances/ sensitivities/ allergies
* Are not currently using any illicit, herbal or recreational drugs including alcohol and nicotine products
* Are not currently taking prescription medications
* Have not taken dietary supplements e.g. Vitamins, omega 3 fish oils etc. in the last 4 weeks
* Do not have a diagnosed neurological condition, or learning/behavioural or neurodevelopmental differences (e.g. dyslexia, autism)
* Do not suffer from visual (including colour blindness) impairment that cannot be corrected with glasses or lenses (that may impact task performance in the opinion of the PI).
* Do not have any pre-existing diagnosed medical condition/illness which will impact taking part in the study
* Consume less than 250 mg/day of caffeine.
* Can complete all of the study assessments at the training visit
* Are not currently participating in other clinical or nutrition intervention studies, or have in the past 4 weeks
* Are compliant with regards to treatment consumption
* Have not taken antibiotics within the past 4 weeks
* Do not have any health condition that would prevent fulfilment of the study requirements (this includes non-diagnosed conditions for which no medication may be taken)
Minimum Eligible Age

8 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Finzelberg GmbH

INDUSTRY

Sponsor Role collaborator

Northumbria University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philippa Jackson, PhD

Role: PRINCIPAL_INVESTIGATOR

Northumbria University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Brain, Performance, Nutrition Research Centre, Northumbria University

Newcastle upon Tyne, Tyne & Wear, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

48CD1

Identifier Type: -

Identifier Source: org_study_id